In a phase 2 trial, lenvatinib produced an objective response rate of about 3%.
Complete response rates were similar whether patients received consolidation or not.
The 1-year overall survival rate was 71%.
Improvements were seen in event-free and overall survival.
The combination improved invasive disease-free survival and distant relapse-free survival.
Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
Researchers sought to determine whether a combination therapy of romidepsin and lenalidomide would be effective as initial therapy for patients with PTCL.
Researchers sought to determine whether idecabtagene vicleucel would have durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Researchers sought to determine whether penpulimab would have efficacy and a low rate of serious AEs in patients with relapsed/refractory classic Hodgkin lymphoma.
